Human papillomavirus type 16 genomic DNA (HPV-16 DNA)

Human papillomavirus type 16 (HPV-16) genomic DNA is a circular, double-stranded DNA molecule of approximately 7.9 kilobases that serves as the genetic template for the virus's life cycle and its pathogenic effects (Source: NCBI, 2024). It is organized into three functional regions: the early region encoding proteins E1-E7 involved in replication and oncogenesis, the late region encoding L1 and L2 capsid proteins, and a non-coding long control region (LCR). HPV-16 is the most prevalent high-risk HPV type, and the persistence of its genomic DNA, often following integration into the host cell genome, is a primary driver of cervical, oropharyngeal, and other anogenital cancers (Source: National Cancer Institute, 2023). Integration typically leads to the disruption of the E2 gene, resulting in the constitutive overexpression of E6 and E7 oncoproteins, which degrade the host tumor suppressors p53 and pRb, respectively. Therapeutic strategies targeting the HPV-16 DNA include gene-editing technologies like CRISPR/Cas9 and TALENs designed to selectively disable viral genes, as well as diagnostic tools that detect viral DNA for early cancer screening (Source: PubMed, PMID: 28431244). Additionally, small molecule antivirals and antisense oligonucleotides are being explored to inhibit the replication and expression of this viral genome.

Other names

HPV16 genomeHuman papillomavirus 16 DNAHPV-16 dsDNAHuman papillomavirus type 16 chromosome

Direct cleavage and degradation of viral DNA sequences, inhibition of viral DNA polymerase, or interference with the transcription of viral oncoproteins E6 and E7 (Source: PubMed, PMID: 25733058, 24409178).